Century Therapeutics, Inc. (IPSC)

Market Cap	47.83M
Revenue (ttm)	114.90M
Net Income (ttm)	-21.94M
Shares Out	86.16M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214,227
Open	0.5605
Previous Close	0.5550
Day's Range	0.5501 - 0.5643
52-Week Range	0.3418 - 3.2900
Beta	1.78
Analysts	Strong Buy
Price Target	3.33 (+499.89%)
Earnings Date	Aug 7, 2025

About IPSC

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineer...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: IPSC
• Website: https://www.centurytx.com

Financial Performance

In 2024, Century Therapeutics's revenue was $6.59 million, an increase of 194.81% compared to the previous year's $2.24 million. Losses were -$126.57 million, -7.40% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for IPSC stock is "Strong Buy." The 12-month stock price target is $3.33, which is an increase of 499.89% from the latest price.

Price Target

$3.33

(499.89% upside)

Analyst Consensus: Strong Buy